Hepatitis C clinical trials

Explore recruiting hepatitis c clinical trials.

Recruiting hepatitis c studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hepatitis C trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Open-Label Study to Assess the Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects with Chronic Hepatitis C Virus (HCV) Infection

Romania, Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study

Romania, France, Germany, Greece, Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A single-arm phase II study of cetuximab plus platinum and taxane-based chemotherapy followed by AVElumab and Cetuximab as first-line therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients with PD-L1 combined positive score (CPS)≥1≤19: the immunotherapy.

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, efficacy and safety phase 3 study of an intravenous human plasma-derived C1 esterase inhibitor (C1-INH) concentrate in participants with congenital C1-INH deficiency for the treatment and pre-procedure prevention of acute hereditary angioedema attacks

Romania, Bulgaria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hepatitis C trials by city

Hepatitis C in Toronto Hepatitis C in Vancouver Hepatitis C in Montreal Hepatitis C in Calgary Hepatitis C in Edmonton Hepatitis C in Ottawa Hepatitis C in Winnipeg Hepatitis C in Quebec City Hepatitis C in Hamilton Hepatitis C in Kitchener Hepatitis C in London Hepatitis C in Halifax Hepatitis C in New York Hepatitis C in Los Angeles Hepatitis C in Chicago Hepatitis C in Houston

Other conditions

Liver cancer Glioblastoma Head and neck cancer Cervical cancer Endometrial cancer Gastric cancer Age-related macular degeneration Diabetic retinopathy Glaucoma Dry eye disease HIV Hepatitis B COVID-19 Influenza RSV Sickle cell disease Anemia Hemophilia Thalassemia Chronic pain Low back pain Smoking cessation Tinnitus Hearing loss